Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Salado, Clarisa ^a   Olaso, Elvira ^b   Gallot, Natalia ^c   Valcarcel, Maria ^c   Egilegor, Eider ^c   Mendoza, Lorea ^c   Vidal Vanaclocha, Fernando ^d  

^a Innoprot SL   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Pharmakine Ltd   (Spain)

^d UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; RESVERATROL; VASCULAR CELL ADHESION MOLECULE 1; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER INFILTRATION; CELL ACTIVATION; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER METASTASIS; LIVER SINUSOID; MALE; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CANCER TRANSPLANTATION; ENDOTHELIUM; EXPERIMENTAL MELANOMA; LIVER; LIVER TUMOR; METABOLISM; METASTASIS; MICROVASCULATURE; PATHOLOGY; SECRETION; TUMOR MICROENVIRONMENT; VASCULARIZATION;

ANIMALS; CELL ADHESION; CELL PROLIFERATION; ENDOTHELIUM; INFLAMMATION; INTERLEUKIN-18; LIVER; LIVER NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROVESSELS; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; STILBENES; TUMOR MICROENVIRONMENT; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79955836106     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-59     Document Type: Article

References (32)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-45. 10.1016/S0140-6736(00)04046-0, 11229684.
2. Vidal-Vanaclocha F. The prometastatic microenvironment of the liver. Cancer Microenvironment 2008, 1:113-29. 10.1007/s12307-008-0011-6, 2654354, 19308690.
3. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002, 50:3337-40. 10.1021/jf0112973, 12010007.
4. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-20. 10.1126/science.275.5297.218, 8985016.
5. Bishayee A, Barnes KF, Bhatia D, Darvesh AS, Carroll RT. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res 2010, 3:753-763.
6. Bishayee A. Cancer Prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009, 2:409-418.
7. Johnson GE, Ivanov VN, Hei TK. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 2008, 13:790-802. 10.1007/s10495-008-0212-y, 18454317.
8. Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M, Darvesh AS. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharmaceutical Research 2010, 27:1080-1091. 10.1007/s11095-010-0144-4, 20405173.
9. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 2008, 314:1163-76. 10.1016/j.yexcr.2007.12.012, 18222423.
10. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 2005, 4:1465-74. 10.1158/1535-7163.MCT-05-0198, 16227395.
11. Huang C, Ma W, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999, 20:237-42. 10.1093/carcin/20.2.237, 10069459.
12. Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther 2008, 7:3751-60. 10.1158/1535-7163.MCT-08-0562, 19074850.
13. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martín JJ, Carrascal T, Walsh P, Reznikov LL, Kim S-H, Novick D, Rubinstein M, Dinarello CA. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Nat Acad Sci USA 2000, 97:734-39. 10.1073/pnas.97.2.734, 15399, 10639148.
14. Vidal-Vanaclocha F, Amezaga C, Asumendi A, Kaplanski G, Dinarello CA. Interleukin-1 Receptor Blockade Reduces the Number and Size of Murine B16 Melanoma Hepatic Metastases. Cancer Res 1994, 54:2667-72.
15. Carrascal TL, Mendoza M, Vacarcel C, Salado E, Egilegor N, Telleria F, Vidal-Vanaclocha, Dinarello C. Interleukin-18 binding protein reduces B16 Melanoma Hepatic Metastasis by neutralizing the adhesiveness and growth factors of sinusoidal endothelial cell. Cancer Res 2003, 63:491-7.
16. Mendoza L, Carrascal T, De Luca M, Fuentes AM, Salado C, Blanco J, Vidal-Vanaclocha F. Hydrogen peroxide mediates vascular cell adhesion molecule-1 expression from interleukin-18-activated hepatic sinusoidal endothelium: implications for circulating cancer cell arrest in the murine liver. Hepatology 2001, 34:298-310. 10.1053/jhep.2001.26629, 11481615.
17. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcarcel M, Gallot N, Carrascal T, Egilegor E, Beaskoetxea J, Dinarello. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006, 25:417-34. 10.1007/s10555-006-9013-3, 17001512.
18. Olaso E, Salado C, Egilegor E, Gutierrez V, Santisteban A, Sancho-Bru P, Friedman SL, Vidal-Vanaclocha F. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003, 37:674-85. 10.1053/jhep.2003.50068, 12601365.
19. Shibata M, Hirota M, Nozawa F, Okabe A, Kurimoto M, Ogawa M. Increased concentrations of plasma IL-18 in patients with hepatic dysfunction after hepatectomy. Cytokine 2000, 12:1526-30. 10.1006/cyto.2000.0740, 11023668.
20. Mendoza L, Valcarcel M, Carrascal T, Egilegor E, Salado C, Sim BK, Vidal-Vanaclocha F. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Cancer Res 2004, 64:304-10. 10.1158/0008-5472.CAN-03-1829, 14729638.
21. Kimura Y, Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 2001, 131:1844-9.
22. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argilés JM, López-Soriano FJ. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 2007, 245:144-8. 10.1016/j.canlet.2005.12.035, 16466851.
23. Castillo-Pichardo L, Martínez-Montemayor MM, Martínez JE, Wall KM, Cubano LA, Dharmawardhane S. Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols. Clin Exp Metastasis 2009, 26:505-16. 10.1007/s10585-009-9250-2, 2898569, 19294520.
24. Ara C, Kirimlioglu H, Karabulut AB, Coban S, Ay S, Harputluoglu M, Kirimlioglu V, Yilmaz S. Protective effect of resveratrol against oxidative stress in cholestasis. J Surg Res 2005, 12:112-7.
25. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, Gharbi N, Kamoun A, El-Fazaa S. Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol and Alcoholism 2006, 41:236-9. 10.1093/alcalc/agh256, 16517551.
26. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998, 27:1265-74. 10.1002/hep.510270512, 9581680.
27. Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 2009, 115:859-68. 10.1002/cncr.24100, 19140204.
28. Cao Q, Cai W, Niu G, He L, Chen X. Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res 2008, 14:6137-45. 10.1158/1078-0432.CCR-08-0049, 18829492.
29. Cho D, Song H, Kim YM, Houh D, Hur DY, Park H, Yoon D, Pyun KH, Lee WJ, Kurimoto M, Kim YB, Kim YS, Choi I. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 2000, 60:2703-9.
30. Schwarz A, Maeda A, Ständer S, van Steeg H, Schwarz T. IL-18 reduces ultraviolet radiation-induced DNA damage and thereby affects photoimmunosuppression. J Immunol 2006, 176:2896-901.
31. Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 2007, 56:1787-97. 10.1002/art.22705, 17530707.
32. Yumoto E, Higashi T, Nouso K, Nakatsukasa H, Fujiwara K, Hanafusa T, Yumoto Y, Tanimoto T, Kurimoto M, Tanaka N, Tsuji T. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol 2002, 17:285-94. 10.1046/j.1440-1746.2002.02690.x, 11982699.